000157416 001__ 157416
000157416 005__ 20240229123137.0
000157416 0247_ $$2doi$$a10.1186/s13053-020-00146-x
000157416 0247_ $$2pmid$$apmid:32760473
000157416 0247_ $$2pmc$$apmc:PMC7393828
000157416 0247_ $$2ISSN$$a1731-2302
000157416 0247_ $$2ISSN$$a1897-4287
000157416 0247_ $$2altmetric$$aaltmetric:86939768
000157416 037__ $$aDKFZ-2020-01611
000157416 041__ $$aeng
000157416 082__ $$a610
000157416 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000157416 245__ $$aInforming patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example.
000157416 260__ $$aHeidelberg$$bSpringer$$c2020
000157416 3367_ $$2DRIVER$$aarticle
000157416 3367_ $$2DataCite$$aOutput Types/Journal article
000157416 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683808667_11660
000157416 3367_ $$2BibTeX$$aARTICLE
000157416 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157416 3367_ $$00$$2EndNote$$aJournal Article
000157416 500__ $$a#EA:C050#EA:C020#LA:B070#LA:C050
000157416 520__ $$aWhen germline mutations are suspected as causal in cancer, patient DNA may be sequenced to detect variants in relevant genes. If a particular mutation has not been reported in reliable family studies, genetic counselors are facing a dilemma of appropriately informing patients. Many sequencing facilities provide an interpretation of the findings based on the available sequence databases or on prediction tools that are curated from bioinformatics and mechanistic datasets. The counseling dilemma is exacerbated if the pedigree data are not informative but the in silico predictions suggest pathogenicity.We present here a real world example of the c.256G > A CDKN2A variant, which was detected in one melanoma patient where two siblings were diagnosed with melanoma in situ. We investigated a detailed family history of the affected siblings in order to survey probability of the cancer risks within the context to this mutation.This c.256G > A CDKN2A variant was detected in one of the brothers and in the melanoma-free mother while the other brother in the family tested negative. The variant had been previously described in one patient from a melanoma family. In the family under investigation, the mother's 16 first-and second-degree relatives had survived past the median onset age for melanoma and none presented melanoma. We tested the variant using multiple bioinformatic tools that all predicted deleteriousness of the variant. The genetic counseling report to the melanoma patient stated that the CDKN2A variant was 'likely pathogenic' and the disease was defined as 'likely hereditary melanoma'.The pedigree data showed at the most a low penetrance variant, which, if taken into consideration, might have altered the provided diagnosis. When dealing with 'practically' unknown variants the counselors would be advised to incorporate a detailed family history rather than basing predictions on functionality provided by sequencing facilities.
000157416 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000157416 588__ $$aDataset connected to CrossRef, PubMed,
000157416 7001_ $$0P:(DE-He78)43b43c5f20ed70299251a446ad8ec973$$aSrivastava, Aayushi$$b1$$udkfz
000157416 7001_ $$0P:(DE-HGF)0$$aRachakonda, Sivaramakrishna$$b2
000157416 7001_ $$0P:(DE-He78)b11ccde1801d45d32a6a60f7b396d7dc$$aBandapalli, Obul$$b3$$udkfz
000157416 7001_ $$aNagore, Eduardo$$b4
000157416 7001_ $$aHemminki, Akseli$$b5
000157416 7001_ $$0P:(DE-He78)9a9af43c15771eaf3b2db8bb28a2829d$$aKumar, Rajiv$$b6$$eLast author$$udkfz
000157416 773__ $$0PERI:(DE-600)2233352-6$$a10.1186/s13053-020-00146-x$$gVol. 18, no. 1, p. 15$$n1$$p15$$tHereditary cancer in clinical practice$$v18$$x1897-4287$$y2020
000157416 909CO $$ooai:inrepo02.dkfz.de:157416$$pVDB
000157416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000157416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)43b43c5f20ed70299251a446ad8ec973$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000157416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000157416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b11ccde1801d45d32a6a60f7b396d7dc$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000157416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9a9af43c15771eaf3b2db8bb28a2829d$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000157416 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000157416 9141_ $$y2020
000157416 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHERED CANCER CLIN PR : 2018$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2020-01-16
000157416 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-16
000157416 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-16
000157416 9202_ $$0I:(DE-He78)B070-20160331$$kB070$$lB070 Funktionelle Genomanalyse$$x0
000157416 9202_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x1
000157416 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000157416 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000157416 9201_ $$0I:(DE-He78)B070-20160331$$kB070$$lB070 Funktionelle Genomanalyse$$x2
000157416 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000157416 9200_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000157416 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000157416 980__ $$ajournal
000157416 980__ $$aVDB
000157416 980__ $$aI:(DE-He78)C050-20160331
000157416 980__ $$aI:(DE-He78)B062-20160331
000157416 980__ $$aI:(DE-He78)B070-20160331
000157416 980__ $$aI:(DE-He78)HD01-20160331
000157416 980__ $$aUNRESTRICTED